Are you a Health Professional? Jump over to the doctors only platform. Click Here

Dr Chris Twelves on Capecitabine and Docetaxel – the development of new anti-cancer drugs and new treatment options for breast cancer.

Print Friendly, PDF & Email

Dr Chris Twelves from the University of Glasgow is involved with the development of new anti-cancer drugs and the CRC Clinical Trials Committee.

What does Xeloda (Capecitabine) plus Taxotere (Docetaxel) mean for the patient, her doctors and nurses?

‘If anyone had Metastatic Breast Cancer, half would be here next Christmas treated with Docetaxel alone, verses two-thirds if treated with combination’, said Dr Twelves.

With metastatic breast cancer, generally speaking, poor quality of life is due to the disease rather than the treatment. Many patients fear that chemotherapy reduces their quality of life however it is actually the disease. He said that a trial of about 20yrs ago that compared hormonal therapy for Metastatic Breast Cancer v chemotherapy, QOL was better in the chemotherapy arm than hormonal, because the treatment was more effective.

Reviewing the phase III trial data under discussion, it was definite that the Capecitabine combination was no worse for QOL than single agent Docetaxel. The global health status improved with time verses single agent treatment.

The main impact on QOL in combination was hand foot syndrome. Some discussion was given to preventing this with pyridoxine (vitamin B6).

Coming tomorrow will be a discussion by Professor Debu Tripathy on the current and future status of Herceptin.



Print Friendly, PDF & Email

Dates

Posted On: 25 November, 2002
Modified On: 3 December, 2013

Tags



Created by: myVMC